期刊文献+

结直肠癌常用化疗药引起肝损伤的研究 被引量:4

A study of the liver injury induced by the common used chemotherapy drugs in colorectal cancer
下载PDF
导出
摘要 目的:以奥沙利铂、伊立替康等为主的化疗方案在结直肠癌肝转移中的应用逐渐增加,但目前一些临床观察表明,化疗可能影响肝脏损伤,进而影响新辅助化疗后围手术期的死亡率。本研究的目的是在健康小鼠腹腔中注射常用化疗药,明确应用不同化疗药引起肝损伤的类型及严重程度。方法:昆明小鼠反复腹腔注射生理盐水或伊立替康、奥沙利铂、5-FU/伊立替康及5-FU/奥沙利铂联合化疗。注射后处死小鼠,以组织学改变评估肝脏损伤类型。结果:在最大可耐受剂量下使用各种化疗药物,肝组织学未显示脂肪变性、纤维化或炎性浸润。与仅接受生理盐水腹腔注射的小鼠相比,接受5-FU/奥沙利铂联合化疗后小鼠肝组织VEGF mRNA表达水平无显著差异。结论:在无肿瘤负荷前提下,以5-FU、伊立替康、奥沙利铂为主的化疗,无肝损伤发生。此外,联合治疗也没有引起组织学改变。 Objective:Oxaliplatin or irinotecan in combination with 5-fluorouracyl(5-FU)and folinic acid are increasingly used in metastatic colorectal cancer to the liver before surgery. Some clinical observations have suggested that chemotherapy may induce liver damage,further more increase the per-operation fatal rate. The aim of this study was to evaluate the type and severity of the liver injury induced by the common used chemical therapy drugs with in-traperitoneal injection these drugs on health mice. Methods:KM mice accepted repeated intraperitoneal with different chemotherapy treatments,including saline,5-FU,irinotecan,oxaliplatin,a combination of 5 -FU/irinotecan or 5 -FU/oxaliplatin. After putted to death,morphological analyses were use to confirm the possible cause of the liver dam-age. Results:A variety of chemotherapeutic agents used at maximum tolerated doses compatible with survival,these regimens did not affect liver injury. Liver histology showed no steatosis,fibrosis or inflammation. The VEGF mRNA ex-pression between the mice treated with combined regimen of 5-FU/oxaliplatin and that accepted saline intraperitone-al injection showed no difference. Conclusion:Without tumor burden,the chemical therapy regimens including 5 -FU,irinotecan,oxaliplatin and combined treatments with 5-FU/irinotecan,5-FU/oxaliplatin induced no liver injury.
作者 王晓芳 王颖
出处 《现代肿瘤医学》 CAS 2014年第6期1264-1268,共5页 Journal of Modern Oncology
基金 沈阳市科学技术项目(编号:F13-318-1-69)
关键词 结直肠癌 新辅助化疗 化疗相关肝损伤 脂肪变性 肝窦梗阻综合征 VEGF colorectal cancer neoadjuvant chemotherapy chemotherapy-induced hepatic injury chemotherapy-associated steatohepatitis sinusoidal obstruction syndrome( SOS) vascular endothelial growth factor
  • 相关文献

参考文献15

  • 1Robinson SM,Wilson CH,Burt AD,et al.Chemotherapy-associated liver injury in patients with colorectal liver metastases:A systematic review and meta-analysis [J].Ann Surg Oncol,2012,19(13):4287-4299.
  • 2Clavien PA,Petrowsky H,DeOliveira ML,et al.Strategies for safer liver surgery and partial liver transplantation [J].N Engl J Med,2007,356:1545-1559.
  • 3Khatri VP,Petrelli NJ,Belghiti J,et al.Extending the frontiers of surgical therapy for hepatic colorectal metastases:is there alimit[J]? Clin Oncol,2005,23:8490-8499.
  • 4Ji YK,Jin SK,Moo JB,et al.Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis[J].Cancer Chemother Phamacol,2013,72(1):223-230.
  • 5Pawlik TM,Olino K,Gleisner AL,et al.Preoperative chemotherapy for colorectal liver metastases:impact on hepatic histology and postoperative outcome [J].J Gastrointest Surg,2007,11:860-868.
  • 6Welsh FK,Tilney HS,Tekkis PP,et al.Safe liver resection following chemotherapy for colorectal metastases is a matter of timing [J].Br J Cancer,2007,96:1037-1042.
  • 7Fernandez FG,Ritter J,Goodwin JW,et al.Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases [J].J Am Coll Surg,2005,200:845-853.
  • 8Karoui M,Penna C,Amin-Hashem M,et al.Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases[J].Ann Surg,2006,243:1-7.
  • 9Vauthey JN,Pawlik TM,Ribero D,et al.Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases [J].J Clin Oncol,2006,24:2065-2072.
  • 10Kandutsch S,Klinger M,Hacker S,et al.Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases[J].Eur J Surg Oncol,2008,34:1231-1236.

同被引文献37

  • 1陈孝治.瑞甘[J].中南药学,2004,2(4):254-255. 被引量:31
  • 2孙燕,周际星.临床肿瘤内科手册[M]第3版.北京:人民卫生出版社,1996:30.
  • 3Grungreiff K, Lambert-Baumann J. Efficacy of L-ornithine- L-aspartate granules in chronic liver disease[J]. Medizinische Welt,2001,52:219-226.
  • 4Jiang Y, Chen L, Wu SM. Clinical application and pharmacological effect of L-omithine-L-aspartate[J]. World J Infect,2007,7:415-418.
  • 5Pauli-Magnus C, Meierp J, Stieger B. Genetic determinants of drug-induced cholestasis and intrahepatic cholestasis ofpregnancy[J]. Semin Liver Dis,2010,30:147-159.
  • 6冯艳.112例药物性肝损害临床分析[J].医学信息,2013,22:629.
  • 7Dos Santos NA, Martins NM, Curti C, et al. Dimethylthiourea protects against mitochondrial oxidative damage induced by cisplatin in liver of rats[J]. Chem Biol Interact,2007,15,170" 177-86.
  • 8Bibeau F, Gil H, Castan F, et al. Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab[J]. Br J Cancer,2013,109:3127-3129.
  • 9程多,姜军,赵君慧.化疗药物引起的药物性肝损伤的研究进展[J].医学信息,2015,28:356.
  • 10张海峰,高静,林娜,夏明.环磷酰胺致肝损伤时肝细胞线粒体的变化[J].江苏大学学报(医学版),2008,18(1):19-22. 被引量:20

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部